技术路线博弈与市场格局重塑下的产业破局之道。重组胶原蛋白“械三证”(第三类医疗器械注册证)争夺战进入白热化阶段!根据国家药监局药品审评中心最新公示,截至2025年12月22日,重组胶原蛋白“械三类”受理品种共有4个。其中,陕西巨子生物技术有限公司占据2席(重组胶原蛋白冻干纤维、重组胶原蛋白植入剂),江苏创健医疗科技股份有限公司同样申报2款产品(重组Ⅲ型胶原蛋白植入剂、重组Ⅲ型胶原蛋白冻干纤维)。...
Source Link技术路线博弈与市场格局重塑下的产业破局之道。重组胶原蛋白“械三证”(第三类医疗器械注册证)争夺战进入白热化阶段!根据国家药监局药品审评中心最新公示,截至2025年12月22日,重组胶原蛋白“械三类”受理品种共有4个。其中,陕西巨子生物技术有限公司占据2席(重组胶原蛋白冻干纤维、重组胶原蛋白植入剂),江苏创健医疗科技股份有限公司同样申报2款产品(重组Ⅲ型胶原蛋白植入剂、重组Ⅲ型胶原蛋白冻干纤维)。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.